• 1
    Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschênes M, Marotta PJ, et al. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol 2009; 23: 180184.
  • 2
    Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528540.
  • 3
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 12071217.
  • 4
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 24172428.
  • 5
    Yong C-L, Scherer J, Sabo J, Stern JO, Steinmann G, Bücher W. BI 201335 pharmacokinetics and early effect on viral load in HCV genotype-1 patients [Abstract 1249]. J Hepatol 2011; 54(Suppl 1):S493.
  • 6
    Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, et al. Potency, safety and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 11141122.
  • 7
    Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatol 2013. doi: 10.1002/hep.26276. [Epub ahead of print].
  • 8
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103107.
  • 9
    Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209.
  • 10
    McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580593.
  • 11
    Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial [Abstract 2]. J Hepatol 2012; 56(Suppl 1):S1S2.
  • 12
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 14331444.
  • 13
    Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 17671777.
  • 14
    Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters [Abstract 278]. Hepatology 2010; 52(Suppl 1):S461A.
  • 15
    Sane R, Podila L, Mathur A, Mease K, Taub M, Huang Q, et al. Mechanisms of isolated unconjugated hyperbilirubinaemia induced by the HCV NS3/4A protease inhibitor BI 201335 [Abstract 1236]. J Hepatol 2011; 54(Suppl 1):S488.